Did cancer clinical trials stay on track at ASCO 2019?

Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference. pharmaphorum spoke with three experts from Kantar to discuss the most interesting developments and trends in cancer that emerged at the event.

ASCO 2019 is over for another year and it’s time to take stock of the latest developments in cancer care unveiled at the conference.

Developments in pancreatic cancer
With so many companies vying to make their case through new research findings for their various drugs and therapies, it takes something really special to make an impact at McCormick Place.

And it was AstraZeneca and Merck & Co that provided one of the highlights, with new data providing hope for certain patients with pancreatic cancer.

• Read the full article in pharmaphorum's Deep Dive digital magazine